Misoprostol Vaginal Insert (MVI) 100, 150, 200 mcg for Cervical Ripening and Induction of Labor

PHASE2CompletedINTERVENTIONAL
Enrollment

374

Participants

Timeline

Start Date

April 30, 2009

Primary Completion Date

December 31, 2009

Study Completion Date

December 31, 2009

Conditions
Cervical RipeningInduction of Labor
Interventions
DRUG

MVI 100

Dose reservoir of 100 mcg of misoprostol in a hydrogel polymer vaginal insert within a retrieval system. The MVI 100 will be kept in place for up to 24 hours or will be removed earlier if one of the following occur: onset of active labor, intrapartum adverse event necessitating discontinuation of the study drug, other reasons including maternal request.

DRUG

MVI 150

Dose reservoir of 150 mcg of misoprostol in a hydrogel polymer vaginal insert within a retrieval system. The MVI 150 will be kept in place for up to 24 hours or will be removed earlier if one of the following occur: onset of active labor, intrapartum adverse event necessitating discontinuation of the study drug, other reasons including maternal request.

DRUG

MVI 200

Dose reservoir of 200 mcg of misoprostol in a hydrogel polymer vaginal insert within a retrieval system. The MVI 200 will be kept in place for up to 24 hours or will be removed earlier if one of the following occur: onset of active labor, intrapartum adverse event necessitating discontinuation of the study drug, other reasons including maternal request.

Trial Locations (11)

19140

Temple University Hospital, Philadelphia

27103

Forsyth Medical Center, Winston-Salem

27710

Duke University Medical Center, Durham

29605

Greenville Hospital System, Greenville

37920

University of Tennesse Medical Center, Knoxville

77030

University of Texas Health Sciences Center at Houston, Houston

85032

Precision Trials, Phoenix

85716

Tuscon Medical Center, Tucson

87131

University of New Mexico Medical Center, Albuquerque

90806

Long Beach Memorial Medical Center, Long Beach

92868

UCI Medical Center, Orange

Sponsors
All Listed Sponsors
lead

Ferring Pharmaceuticals

INDUSTRY